PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH,Liver International

当前位置： X-MOL 学术 › Liver Int. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

PPAR-γ-induced changes in visceral fat and adiponectin levels are associated with improvement of steatohepatitis in patients with NASH
Liver International ( IF 6.0 ) Pub Date : 2021-07-05 , DOI: 10.1111/liv.15005
Amalia Gastaldelli _{1,

2} , Silvia Sabatini _{2,

3} , Fabrizia Carli ₂ , Melania Gaggini ₂ , Fernando Bril ₄ , Renata Belfort-DeAguiar ₅ , Vincenzo Positano ₆ , Diana Barb ₄ , Sushma Kadiyala _{4,

7} , Stephen Harrison ₈ , Kenneth Cusi _{4,

7}

Affiliation

Peroxisome proliferator-activated receptor (PPAR)-γ agonists decrease hepatic/visceral fat (VF) and improve necroinflammation despite subcutaneous (SC) fat weight-gain. Understanding the impact of changes in VF, VF-to-SC fat distribution (VF/SC) and adiponectin (ADPN) levels in relation to histological improvement after weight-loss or pioglitazone is relevant as novel PPAR-γ agonists are being developed for treating non-alcoholic steatohepatitis (NASH).

中文翻译：

PPAR-γ诱导的内脏脂肪和脂联素水平变化与 NASH 患者脂肪性肝炎的改善有关

尽管皮下 (SC) 脂肪重量增加，过氧化物酶体增殖物激活受体 (PPAR)-γ 激动剂仍可减少肝脏/内脏脂肪 (VF) 并改善坏死性炎症。了解 VF、VF 到 SC 脂肪分布 (VF/SC) 和脂联素 (ADPN) 水平的变化对减肥或吡格列酮后组织学改善的影响是相关的，因为正在开发用于治疗的新型 PPAR-γ 激动剂非酒精性脂肪性肝炎（NASH）。

更新日期：2021-07-05

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文本刊介绍/投稿指南11